From: Zeenews India
Netherlands based RegPak Bio-pharma today announced a tie up with a Taiwan based company Meriyana International Biotechnology to sell Chinese herbal medicine for cancer treatment in India through its Indian subsidiary Cancure (P) Ltd based here.
Announcing this, CEO of RegPak BioPharma Parminder Kaur said:”Doctors have been shortlisted to undergo training in Taiwan to work in the CanCure Clinics to be set up in Chandigarh and later, various parts of Punjab”.
She said a substantial number of patients suffer from cancer in various areas of Punjab and claimed that Chinese medicine would be helpful in treating those patients effectively.
Accompanied by the representatives of Meriyana International, Parminder Kaur said the herbal medicine, Chinmanna, has undergone several clinical trials in Taiwan, and that RegPak would be introducing it very soon in Europe where it has got the approvals to be introduced as compassionate medicine for terminal cancer patients.
Chinmanna is launched for treatment of various types of cancers including breast, stomach, throat, mouth, pancreas, intestinal and spleen cancer, she claimed.
There are precisely no studies into Chinmanna as a treatment for cancer available via pubmed or indeed from various other sources. Indeed a google search of Chinmanna only seems to reveal it’s existence as a medicinal herbs in reports relating to RegPaks intent to sell it.
All of which adds up to a very worrying picture.
Are RegPak marketing an unproven treatment based on anecdote alone to a large proportion of potential patients in India?
If so one wonders if they have even ever heard of medical ethics.